Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors

OncoImmunology

Volumn 4, Issue 6, 2015, Pages

  Pedroza Gonzalez, Alexander ^a,b   Zhou, Guoying ^a   Vargas Mendez, Ernesto ^a   Boor, Patrick PC ^a   Mancham, Shanta ^a   Verhoef, Cornelis ^a   Polak, Wojciech G ^a   Grünhagen, Dirk ^a   Pan, Qiuwei ^a   Janssen, Harry LA ^a   Garcia Romo, Gina S ^c   Biermann, Katharina ^a   Tjwa, Eric T T L ^a   Ijzermans, Jan N M ^a   Kwekkeboom, Jaap ^a   Sprengers, Dave ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Colorectal cancer liver metastasis; Hepatocellular carcinoma; ICOS L; IL 10; Immunotherapy; Tr1 cells

Indexed keywords

ALPHA2 INTEGRIN; CYTOKINE; INDUCIBLE CO STIMULATORY LIGAND; INTERLEUKIN 10; INTERLEUKIN 13; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER INFILTRATION; CD4+ CD25+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; PROTHROMBIN TIME; REGULATORY T LYMPHOCYTE; TUMOR GROWTH;

EID: 85053361612     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1008355     Document Type: Article

References (29)

1. Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 2008; 29:130-43; PMID:18061252; http://dx.doi.org/10.1016/j. mam.2007.09.008
2. Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol 2010; 22:364-73; PMID: 20520544; http://dx.doi.org/10.1097/CCO.0b013e32833a6c8a
3. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012; 1:48-55; PMID:22720211; http://dx.doi.org/10.4161/ onci.1.1.18344
4. Mazzolini G, Ochoa MC, Morales-Kastresana A, Sanmamed MF, Melero I. The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. Immunotherapy 2012; 4:1081-5; PMID:23194355; http://dx.doi.org/10.2217/ imt.12.99
5. Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, Gallegos M, Burton EC, Savino D, Hori T, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011; 208:479-90; PMID:21339324; http://dx.doi.org/10.1084/jem.20102131
6. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
7. + regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013; 57:183-94; PMID:22911397; http://dx.doi.org/ 10.1002/hep.26013
8. Pedroza-Gonzalez A, Kwekkeboom J, Sprengers D. Tcell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment. Oncoimmunology 2013; 2:e22450; PMID:23483229; http://dx.doi.org/10.4161/ onci.22450
9. Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012; 3:30; PMID:22566914; http://dx.doi.org/10.3389/ fimmu.2012.00030
10. Roncarolo MG, Gregori S, Lucarelli B, Ciceri F, Bacchetta R. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev 2011; 241:145-63; PMID:21488896; http://dx.doi.org/ 10.1111/j.1600-065X.2011.01010.x
11. Kakita N, Kanto T, Itose I, Kuroda S, Inoue M, Matsubara T, Higashitani K, Miyazaki M, Sakakibara M, Hiramatsu N, et al. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells. Int J Cancer 2012; 131:2573-83; PMID:22419479; http:// dx.doi.org/10.1002/ijc.27535
12. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62; PMID:14604957; http://dx.doi.org/ 10.1182/blood-2003-07-2594
13. Lundqvist A, Palmborg A, Pavlenko M, Levitskaya J, Pisa P. Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J Immunother 2005; 28:229-35; PMID:15838379; http://dx.doi.org/10.1097/01. cji.0000158854.15664.c2
14. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67:8865-73; PMID:17875728; http://dx. doi.org/10.1158/0008-5472.CAN-07-0767
15. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013; 19:739-46; PMID:23624599; http:// dx.doi.org/10.1038/nm.3179
16. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421:388-92; PMID:12540904; http://dx.doi.org/10.1038/nature01315
17. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717
18. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, Qin XF, Liu YJ, Gilliet M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204:105-15; PMID:17200410; http://dx.doi.org/ 10.1084/jem.20061660
19. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, Anderson S, Atkinson N, Ramirez PT, Liu YJ, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012; 72:5240-9; PMID:22850422; http://dx.doi.org/ 10.1158/0008-5472.CAN-12-2271
20. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71:5423-34; PMID:21697280; http://dx.doi.org/10.1158/ 0008-5472.CAN-11-0367
21. + T cells. Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi.org/10.1158/ 0008-5472.CAN-12-2409
22. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468
23. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, Zheng SS. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6:e24671; PMID:21935436; http://dx.doi.org/10.1371/journal. pone.0024671
24. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127:759-67; PMID:20518016
25. + regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006; 45:254-62; PMID:16600416; http://dx.doi. org/10.1016/j.jhep.2006.01.036
26. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3C T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186-92; PMID:19064967; http://dx.doi.org/ 10.1200/JCO.2008.18.7229
27. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14:3706-15; PMID:18559587; http://dx.doi.org/10.1158/1078-0432.CCR-07-5126
28. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH, Berry G, DeKruyff RH, Umetsu DT. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8:1024-32; PMID:12145647; http://dx. doi.org/10.1038/nm745
29. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; 73:4629-40; PMID:23722543; http://dx.doi.org/10.1158/0008-5472.CAN-12-3058